ATE434434T1 - Zusammensetzungen mit mikronisiertem tanaproget - Google Patents

Zusammensetzungen mit mikronisiertem tanaproget

Info

Publication number
ATE434434T1
ATE434434T1 AT06824718T AT06824718T ATE434434T1 AT E434434 T1 ATE434434 T1 AT E434434T1 AT 06824718 T AT06824718 T AT 06824718T AT 06824718 T AT06824718 T AT 06824718T AT E434434 T1 ATE434434 T1 AT E434434T1
Authority
AT
Austria
Prior art keywords
compositions
hormone
benign
micronized tanaproget
uterine
Prior art date
Application number
AT06824718T
Other languages
English (en)
Inventor
Arwinder Nagi
Ramarao Chatlapalli
Shamim Hasan
Rolland Carson
Mohamed Ghorab
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE434434T1 publication Critical patent/ATE434434T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06824718T 2005-04-28 2006-04-26 Zusammensetzungen mit mikronisiertem tanaproget ATE434434T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67559905P 2005-04-28 2005-04-28
PCT/US2006/016025 WO2007030153A2 (en) 2005-04-28 2006-04-26 Compositions containing micronized tanaproget

Publications (1)

Publication Number Publication Date
ATE434434T1 true ATE434434T1 (de) 2009-07-15

Family

ID=37836301

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06824718T ATE434434T1 (de) 2005-04-28 2006-04-26 Zusammensetzungen mit mikronisiertem tanaproget

Country Status (14)

Country Link
US (2) US8343965B2 (de)
EP (1) EP1874278B1 (de)
JP (3) JP5149161B2 (de)
CN (1) CN101166521A (de)
AT (1) ATE434434T1 (de)
AU (1) AU2006287925B2 (de)
BR (1) BRPI0610438A2 (de)
CA (1) CA2603817C (de)
DE (1) DE602006007453D1 (de)
DK (1) DK1874278T3 (de)
ES (1) ES2327783T3 (de)
MX (1) MX2007013468A (de)
PL (1) PL1874278T3 (de)
WO (1) WO2007030153A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767668B2 (en) * 2005-04-28 2010-08-03 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
BRPI0610438A2 (pt) 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, cápsula, conjunto farmacêutico, e, processo para preparar uma composição
WO2006116596A2 (en) * 2005-04-28 2006-11-02 Wyeth Micronized tanaproget and compostions containing same
MX2007013469A (es) * 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
MX2007015571A (es) 2005-06-09 2008-03-06 Wyeth Corp Composiciones de tanaproget que contienen etinilestradiol.
US20090170823A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
EP2512455B8 (de) 2009-12-18 2014-07-23 FrieslandCampina Nederland Holding B.V. Co-verarbeitete tablettenunterstützungszusammensetzung sowie ihre herstellung und verwendung
EP2545922A1 (de) * 2011-07-12 2013-01-16 PregLem S.A. Behandlung von übermäßiger Monatsblutung im Zusammenhang mit Gebärmutterfibromen
WO2023025672A1 (en) 2021-08-25 2023-03-02 Basf Se Direct tableting auxiliary composition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK95093D0 (da) 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
KR100732692B1 (ko) * 1999-05-04 2007-06-27 와이어쓰 프로게스테론 수용체 조절인자인 시클로티오카르바메이트유도체
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1531824A4 (de) * 2002-06-25 2005-09-21 Wyeth Corp Cyclothiocarbamat-derivate als pr-modulatoren und ihre verwendung bei der behandlung von hauterkrankungen
AU2003247608A1 (en) * 2002-06-25 2004-01-06 Wyeth Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
US20040127476A1 (en) * 2002-11-14 2004-07-01 Alvin Kershman Oral testosterone delivery system with improved sustained release
US8404272B2 (en) * 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
JP5108506B2 (ja) 2004-04-27 2012-12-26 ワイス・エルエルシー シアノピロール含有環式カルバメートおよびチオカルバメートビアリール、およびこれらの製造方法
BRPI0510260A (pt) 2004-04-27 2007-10-23 Wyeth Corp método para purificar um composto, e, kit farmacêutico
AR049707A1 (es) 2004-07-07 2006-08-30 Wyeth Corp Regimenes y kits de progestina ciclica
GT200500183A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AU2005272854B2 (en) * 2004-08-13 2012-04-26 Wyeth Tanaproget derivatives, metabolites, and uses thereof
CN101027321A (zh) 2004-08-20 2007-08-29 惠氏公司 孕酮受体结构
US7767668B2 (en) * 2005-04-28 2010-08-03 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
ES2431324T3 (es) * 2005-04-28 2013-11-26 Wyeth Llc Forma purificada de tanaproget
WO2006116596A2 (en) * 2005-04-28 2006-11-02 Wyeth Micronized tanaproget and compostions containing same
BRPI0610438A2 (pt) 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, cápsula, conjunto farmacêutico, e, processo para preparar uma composição
MX2007013469A (es) 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
MX2007015571A (es) 2005-06-09 2008-03-06 Wyeth Corp Composiciones de tanaproget que contienen etinilestradiol.

Also Published As

Publication number Publication date
ES2327783T3 (es) 2009-11-03
BRPI0610438A2 (pt) 2012-10-23
AU2006287925B2 (en) 2012-03-01
DE602006007453D1 (de) 2009-08-06
WO2007030153A3 (en) 2007-08-09
WO2007030153A2 (en) 2007-03-15
US20130142838A1 (en) 2013-06-06
EP1874278B1 (de) 2009-06-24
EP1874278A2 (de) 2008-01-09
CN101166521A (zh) 2008-04-23
US8343965B2 (en) 2013-01-01
JP2008539264A (ja) 2008-11-13
DK1874278T3 (da) 2009-09-28
PL1874278T3 (pl) 2009-12-31
JP2014205683A (ja) 2014-10-30
AU2006287925A1 (en) 2007-03-15
CA2603817C (en) 2013-03-19
US20060247234A1 (en) 2006-11-02
CA2603817A1 (en) 2007-03-15
US8791109B2 (en) 2014-07-29
JP2012254999A (ja) 2012-12-27
JP5149161B2 (ja) 2013-02-20
MX2007013468A (es) 2008-01-21

Similar Documents

Publication Publication Date Title
CY1110017T1 (el) Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην
TW200716129A (en) Micronized tanaproget, compositions, and methods of preparing the same
TW200716621A (en) Polymorph form II of tanaproget
DE602006007453D1 (de) Zusammensetzungen mit mikronisiertem tanaproget
JP2005511491A5 (de)
CY1118407T1 (el) Αντισωματα εξουδετερωσης υποδοχεα προλακτινης και θεραπευτικη χρηση αυτων
CL2012000166A1 (es) Compuesto (11beta,17beta)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; y su uso para el tratamiento y/o la prevencion de fibroides uterinos, endometriosis, sangrados menstruales severos, meningiomas, cancer de mama hormonodependiente y de trastornos asociados a la menopausia, entre otros.
TW200731969A (en) Use of progesterone receptor modulators
RU2016119135A (ru) Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения
EA201491344A1 (ru) Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона
AU2003255820A1 (en) Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
JP2008539258A5 (de)
NZ515353A (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
MX2009009514A (es) Heterociclos sulfonilados utiles para la modulacion del receptor de progesterona.
CY1109919T1 (el) Παραγωγα της ινδολης που ειναι χρησιμα σα ρυθμιστες του υποδοχεα της προγεστερονης
MX2009009515A (es) Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona.
DOP2006000147A (es) Uso de modulares no esteroides de receptores de progesterona.
JP2008517871A5 (de)
DOP2006000148A (es) Moduladores no esteroides de receptores de progesterona
RU2020138372A (ru) Композиция для лечения одного или нескольких заболеваний, связанных с эстрогеном
黃其民 et al. Surgical Resection Combined with Systemic Imatinib Therapy for the Treatment of Advanced Gastrointestinal Stromal Tumor
Cheng et al. Apoptosis and Endometriosis
AR023854A1 (es) Uso de derivados de indolina y equipo farmaceutico para regimenes ciclicos
AR030018A1 (es) Derivados de benzo(d)(1,3)oxazin-2-ona, composiciones farmaceuticas que los comprenden y el uso de los mismos para preparar medicamentos como moduladores receptores de progesterona

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties